* Kodiak Sciences Inc reported a quarterly adjusted loss of 84 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -95 cents. The mean expectation of six analysts for the quarter was for a loss of 90 cents per share. Wall Street expected results to range from -100 cents to -82 cents per share.
* Reported revenue was zero; analysts expected zero.
* Kodiak Sciences Inc's reported EPS for the quarter was a loss of 84 cents.
* The company reported a quarterly loss of $43.95 million.
* Kodiak Sciences Inc shares had risen by 103.1% this quarter and gained 74.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and 3 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Kodiak Sciences Inc is 3.50 This summary was machine generated from LSEG data November 15 at 11:59 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.90 -0.84 Beat
Jun. 30 2024 -0.87 -0.86 Beat
Mar. 31 2024 -1.07 -0.82 Beat
Dec. 31 2023 -0.77 -1.13 Missed
Comments